台北醫學院(現台北醫學大學)醫學系學士1981 ~1988

和信治癌中心醫院 血液與腫瘤科部 副主任 2020.02.01~2022.06.30
和信治癌中心醫院 血液與腫瘤科部 資深主治醫師 1995~2022.06
和信治癌中心醫院 血液淋巴腫瘤團隊 負責人 2006~2017
和信治癌中心醫院 血液與腫瘤科部 主治醫師 1995~2022.06

中華民國內科醫學會
中華民國癌症醫學會
中華民國血液病醫學會
中華民國血液及骨髓移植醫學會
台灣癌症安寧緩和醫學會

PUBLICATIONS
1. Song YQ, Wu SJ, Tan TD, Ma J, Chang CS, Tse WC et al. Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies. Experimental Hematology & Oncology (2023) 12: 92.
2. Tan TD. Successful eradication of rituximab-refractory post-transplant lymphoproliferative disorder after second haplo-identical allogeneic hematopoietic stem cell transplantation. Journal of Medical Research and Case Reports. 2023; 5 (1).
3. Tan TD. Successful eradication of rituximab-refractory REBV-related post-transplant lymphoproliferative. Disorder after second haplo-identical allogeneic hematopoietic stem cell transplantation for very severe aplastic anemia – a case report. Ann Case Report 2022; 7: 926.
4. Wang YH, Tan TD, Ko BS et al. Stem cell transplant for mantle cell lymphoma in Taiwan. Nature portfolio 2022; 12:5662.
5. Yang KL, Tan TD, Lin PY. Discovery of the novel HLA-DRB1*07:136 allele in a Taiwanese patient. HLA.. 2022; 100(3).
6. Yu-Hung Wang1, Su-Peng Yeh2, Jyh-Pyng Gau3, Po-Nan Wang4, Yi-Chang Liu5,6, Yeu-Chin Chen7, Chieh-Lin Jerry Teng8, Tsai-Yun Chen9, Shih-Chiang Lin10, Tran-Der Tan11, Tso-Fu Wang12, Ming-Chun Ma13, Shyh-Jer Lin14, Chuan-Cheng Wang15, Ming-Yang Lee16, Chih-Cheng Chen17,18, Tsu-Yi Chao19, Shiann-Tang Jou20, Ming Yao1, Bor-Sheng Ko1,21. A review of haematopoietic cell transplantation in Taiwan: data and trends during 2009–2018. 2022 European Hematology Association annual meeting abstract.
7. Prognostic Factors of Poor Survival in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma in Taiwan: A Nationwide Retrospective Study. HemaSphere 2021. European Hematology Association annual meeting, 2021.
8. Tan TD, Chiou LW. Venetoclax and Posaconazole plus standard dose Cytarabine for newly diagnosed AML. Blood. American Society of Hematology annual meeting, 2020.
9. Tan TD, Chiou LW, Wu JS, Lee MY, Huang YY, Chen SS, and LuSM. Long-term rather than short-term survival benefit in mantle cell lymphoma patients treated with intensive chemo-immunotherapy and hematopoietic stem cell transplantation in real world experience. Haematol Int J 2020; 4(2): 00072.
10. Tan TD, Hong YC, Li SS, Yu JT, Sung YC, Wang PN, Teng CL, The multiple myeloma working group, Hematology’s Society of Taiwan. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from Bortezomib-based induction therapies: a prospective, observational study. Chin J Physiol 2020; 63: XX-XX.
11. Tan TD, Chiou LW. Frontline treatment with Venetocalx, Posaconazole, and standard dose Cytarabine or Azacitidine followed by allogeneic hematopoietic stem cell transplantation for newly diagnosed acute myeloid leukemia. HemaSphere 2020, in press.
12. Tan TD, Chiou LW. Intensive chemo-immunotherapy plus hematopoietic stem cell transplantation or non-intensive treatment for mantle cell lymphoma –Real world clinical outcome in single institute experience. HemaSphere 2020, in press.
13. Huang TC, Huang SY, Yao M, Tan TD, et al. Autologous stem cell transplantation in multiple myeloma: post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry. J of the Formosan Medical Association 2019; 118: 471-480.
14. Tan TD, Chiou LW, Wu MC, Wu JS, Lee MY, Huang YY, Chen SS. The Impact of First Complete Remission by PET-CT and Time to Next Treatment on Survival of Follicular lymphoma patients. Clinical Hematology International. In Press, Corrected Proof, Available Online: 7 June 2019.
15. Co-authors. Prognostic value of end-of-induction PET response after first-line immune-chemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomized, phase 3 trial. Lancet Oncol 2018; 19(11): 1530-1542.
16. Huang TC, Huang SY, Yao M, Lin CY, Hwang WL, Tan TD et al. Autologous stem cell transplantation in multiple myeloma: post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry. J Formos Med Assoc. 16 August 2018.
17. Kuo CY, Wang PN, Hwang WL, Tan TD et al. Safety and efficacy of Nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or utterance to Imatinib: result from the NOVEL study. Therapeutic Advances in Hematology 2018; 9(3): 65-78.
18. Hsu YT, Tsai HJ, Chang JS, Li SS, Tan TD et al. Stem cell transplantation for T-cell lymphomas in Taiwan. Bone Marrow Transplantation 2018; 53: 993-1000.
19. Tran-Der Tan, Mau-Ching Wu , Lun-Wei Chiou , Peng-Yu Chen , Ja-Shing Wu. FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE B AND T CELL LYMPHOMA. Haematologica 2016 Jun sup. T.D. Tan, M.-C. Wu, J.L.W. Chiou, A. C. Feng. HBV Clearance in HBsAg+ Patients after Allogeneic Stem Cell Transplantation is Heralded by GVHD of Liver. Haematologica 2015 Jun sup.
20. Ching-Yuan Kuo Po-Nan Wang, Wen Li Hwang, Tran-Der Tan, et al. Safety and efficacy of Nilotinib in patients with chronic phase or accelerated phases Philadelphia chromosome positive chronic myelogenous leukemia with resistance or intolerance to Imatinib Mesylate: results from the multi-center, observational NOVEL study in Taiwan. Blood (ASH Annual Meeting Abstracts) 2015: Poster Abstract.
21. Ko BS, Tan TD, et al. Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement. Int J Hematology 2014; 100(1): 7-15.
22. Win KT, Lee MY, Tan TD et al. Nasopharyngeal alveolar rhabdomyosarcoma expressing CD56: a mimicker of extra nodal natural killer/T-cell lymphoma. Int J Clin Exp Pathol 2013; 7(1): 451-455.
23. T.D. Tan, M.-C. Wu, J.L.W. Chiou. Outcome of second allo-transplantation for relapsed hematologic malignancies after stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2012:120 Abstract 4461.
24. T.D. Tan, M.-C. Wu, J.L.W. Combination of gut GVHD and CMV enterocolitis in allogeneic hematopoietic stem cell transplant patients--10 years’ experience of a single institution. Bone Marrow Transplantation Vol 47, Supplement 1, S164, Apr 2012
25. T.D. Tan. Pulmonary Complications in Hematopoietic Stem Cell Transplant Patients--A Single Institution Experience. Bone Marrow Transplantation Vol 47, Supplement 1, S200, Apr 2012
26. T.D. Tan, M.-C. Wu, J.L.W. Chiou. CD56-Positive Acute Myeloid Leukemia Has Inferior Outcome After Allogeneic Hematopoietic Stem Cell Transplantation (Abstract). Blood (ASH Annual Meeting Abstracts) 2011 118: Abstract 4493.
27. T.D. Tan, M.-C. Wu, J.L.W. Chiou. The impact of velcade treatment on survival of relapsed myeloma patients – A single institution experience. Haematologica 96(s2), p535, 2011.
28. T.D. Tan, M.-C. Wu, J.L.W. Chiou. CD56 positivity is a poor prognostic factor in AML patients undergoing stem cell transplant. Bone Marrow Transplantation Vol 46, Supplement 1, S281, Apr 2011.
29. T.D. Tan, M.-C. Wu, J.L.W. Chiou. Long-term survival of 2Gy TBI and Fludarabine as the RIC conditioning in the treatment of repeated relapsed lymphoma. Bone Marrow Transplantation Vol 46, Supplement 1, S296, Apr 2011.
30. T.D. Tan, M.-C. Wu, J.L.W. Chiou. Long-term survival of mantle cell lymphoma – A single institution experience in Taiwan. Haematologica 2010; 95(s2) p633 (Abstract 1607).
31. T.D. Tan, M.-C. Wu, J.L.W. Chiou. Micafungin prophylaxis in hematopoietic stem cell transplantation – A single institution experience. Haematologica 2010; 95(s2) p728~729 (Abstract 1889).
32. T.D. Tan, M.-C. Wu, J.L.W. Chiou. Treatment of relapsed acute leukemia patients after hematopoietic stem cell transplantation – a single-centre experience. Bone Marrow Transplantation Vol 45, Supplement 2, S418, Mar 2010.
33. T.D. Tan, M.C. Wu, J.L.W. Chiou. Allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute leukemia – a single-center experience. Bone Marrow Transplantation Vol 45, Supplement 2, S94~S95, Mar 2010.
34. L.H. Fang, C.J. Huang, T.D. Tan, et al. Chemotherapy-related delayed bilateral spontaneous pneumothorax and lung fibrosis: methotrexate or cyclophosphamide, or both? Clinical Respiratory Journal 2010 p254~255.
35. Wei-Ting Chen , Ting-Mei Liu, Shih-Hsuan Wu, Tran-Der Tan, Hsiu-Chin Tseng, Chiang-Ching Shih. Improving diagnosis of central venous catheter-related bloodstream infection by using differential time to positivity as a hospital-wide approach at a cancer hospital. Journal of Infection Vol 59 (5); p 317~323 Nov 2009
36. Tran-Der Tan. Addition of Anti-thymocyte Globulin Could Reduce the GVHD and not Increase Mortality in Unrelated Stem Cell Transplantation. Bone Marrow Transplantation Vol 43, Supplement 1, s140~141, March 2009.
37. Tran-Der Tan. CMV Infection in Seropositive Patients with Hematologic Malignancies after Allogeneic Peripheral Blood Stem Cell Transplantation. Bone Marrow Transplantation Vol 43, Supplement 1, s369, March 2009.
38. Tran-Der Tan, M. Lee. The shift of treatment for nasal and nasal-type NK/T cell lymphoma, ten years’ experience and prognostication analysis in a single institution. Haematologica 2007; 92(s1): p263.
39. M. Lee, Tran-Der Tan. Clinicopathological analysis of acute myeloid leukemia in a single institution: phenotypic acute myeloid leukemia may not be an aggressive subtype. J Chin Med Association 2007(7): 269~273.
40. M-Y. Lee, M-H Tsou, Tran-Der Tan, M-C Liu. Clinicopathological analysis of T-cell lymphoma in Taiwan according to WHO classification: high incidence of enteropathy-type intestinal T-cell lymphoma. European J Hematology 2005; 75: 221~226.
41. Ming-Yuan Lee, Tran-Der Tan, An-Chen Feng, and Mei-Ching Liu. Clinicopathological Analysis of 598 Malignant Lymphomas in Taiwan: Seven-Year Experience in a Single Institution. Am J Hematology 2006; 81: 568~575.
42. Stella Y.C. Tsai, Tran-Der Tan, et al. Brain stem doses for patients of T3/T4 nasopharyngeal carcinoma treated by bid irradiation and concomitant chemotherapy. Therapeutic Radiology and Oncology 2005; 12(3): 167~180.
43. S.H. Cheng, Tran-Der Tan et al. Prognostic significance of para-pharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. Int J Radiation Oncology Biol Phys 2005; 61(2): 456~465.
44. S.H. Cheng, Tran-Der Tan et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J of Clin Oncol 2000; 18: 2040~2045.
45. J C Cheng, Tran-Der Tan et al. Prophylactic para-aortic radiotherapy and concomitant chemotherapy for patients with cervical carcinoma: preliminary analysis of outcome and toxicity. Therapeutic Radiology and Oncology 2000; 7(4): 243~251.
46. Mei-Hua Tsou, Tran-Der Tan et al. Case report small cell carcinoma of the uterine cervix with large cell neuroendocrine carcinoma component. Gynecologic Oncology 1998; 68: 69~72.
47. S.H. Cheng, Tran-Der Tan et al. Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int J Radiation Oncology Biol Phys 1998; 41(4): 755~762.

ABSTRACTS/PRESENTATIONS
1. Venetoclax-based therapy followed by allogeneic hematopoietic stem cell transplantation for newly diagnosed AML patients—Single institute experience. Invited Speaker presented at 40-year anniversary celebration of VGH Tai-Chung on Oct 29, 2022.
2. Second Primary Malignancy after Hematopoietic Stem Cell Transplantation. HemaSphere 2022. European Hematology Association annual meeting, 2022.
3. Second Primary Malignancy after Hematopoietic Stem Cell Transplantation. Annual Meeting of Taiwan Society of Hematology, 2022. (Oral presentation)
4. Treatment outcome of Orbital Marginal Zone B cell Lymphoma. Annual Meeting of Taiwan Society of Hematology, 2022. (Oral presentation)
5. Prognostic Factors of Poor Survival in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma in Taiwan: A Nationwide Retrospective Study. HemaSphere 2021. European Hematology Association annual meeting, 2021.
6. Venetocalx and Posaconazole plus standard dose Cytarabine for newly diagnosed AML. Blood. American Society of Hematology annual meeting, 2020.
7. Longer Follow-up of Venetocalx-based Combination Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Annual Meeting of Taiwan Society of Hematology, 2021. (Oral Presentation)
8. Successful eradication of EBV PTLD in a very severe SAA patient. Fall Meeting of Taiwan Society of Hematology, 2021. (Oral presentation)
9. Bowel Ischemia and Rhizopus Fungal after allogeneic hematopoietic stem cell transplant in an AML patient. Winter Meeting of Taiwan Society of Hematology, 2021. (Oral presentation)
10. Mantle Cell Lymphoma, current standard of care and future directions. Onco Virtual Summit 2020; Aug 28 ~ Oct 31, 2020.
11. Frontline treatment with Venetocalx, Posaconazole, and standard dose Cytarabine or Azacitidine followed by allogeneic hematopoietic stem cell transplantation for newly diagnosed acute myeloid leukemia. 2020 annual meeting of EHA, Frankfort, Germany, June 11, 2020.
12. Intensive chemo-immunotherapy plus hematopoietic stem cell transplantation or non-intensive treatment for mantle cell lymphoma –Real world clinical outcome in single institute experience. 2020 annual meeting of EHA, Frankfort, Germany, June 11, 2020.
13. Similar outcome of mantle cell lymphoma patients undergoing early or late hematopoietic stem cell transplantation- on behalf of Taiwan Society of Blood and Marrow transplantation. Oral presentation, APBMT 2019, Busan, South Korea.
14. Allogeneic hematopoietic stem cell transplantation can overcome the poor outcome of adult Ph(+) acute lymphoblastic leukemia- on behalf of Taiwan Society of Blood and Marrow Transplantation. Poster presentation, 2019 annual meeting of EHA, Amsterdam, Holland, June 15, 2019.
15. Evolving treatment strategy and disease management in Follicular lymphoma. Hematology Master Club, oral presentation, Seoul, June 28, 2019.
16. Allogeneic hematopoietic stem cell transplantation of acute lymphoblastic leukemia -on behalf of Taiwan Society of Blood and Marrow Transplantation. Annual Meeting of Taiwan Society of Hematology, 2019. (Oral presentation)
17. Allogeneic hematopoietic stem cell transplantation of acute lymphoblastic leukemia -on behalf of Taiwan Society of Blood and Marrow Transplantation. Guest Speaker of annual meeting of International Congress of Korea Society of Hematology. Seoul, South Korea, Mar 16, 2019.
18. The Impact of First Complete Remission by PET-CT and Time to Next Treatment on Survival of Follicular lymphoma patients. Annual Meeting of Taiwan Society of Hematology, 2018. (Oral presentation)
19. Outcome of autologous and allogeneic stem cell transplantation for lymphoma -single institution experience. Annual Meeting of Taiwan Society of Hematology, 2016. (Oral presentation)
20. Frontline autologous stem cell transplantation for aggressive B and T cell lymphoma. Annual Meeting of European Hematology Association 2016. (E-poster presentation)
21. Clearance of HBV after allogeneic stem cell transplantation. Annual Meeting of Taiwan Society of Hematology, 2014. (Oral presentation)
22. What is the choice of HSCT conditioning when BEAM is subsided? Northern Taiwan 2014 Spring Meeting of TSBMT. Secondary Acute Leukemia after Chemotherapy in Breast Cancer. Seasonal Meeting of Taiwan Society of Hematology, 2013.
23. Outcome of second allo-transplantation for relapsed hematologic malignancies after stem cell transplantation. Annual Meeting of Taiwan Society of Hematology, 2013. (Oral presentation)
24. Outcome of second allo-transplantation for relapsed hematologic malignancies after stem cell transplantation. EBMT 2013 (Poster presentation).
25. Combination of gut GVHD and CMV enterocolitis in allogeneic hematopoietic stem cell transplant patients -10 years’ experience of a single institution. EBMT 2012. (Poster presentation)
26. Pulmonary Complications in Hematopoietic Stem Cell Transplant Patients--A Single Institution Experience. EBMT 2012. (Poster presentation)
27. General treatment of Ph(+) acute lymphoblastic leukemia. Educational Lecture on Taiwan Society of Hematology and Taiwan Society of Blood and Bone Marrow Transplantation. National Taiwan University Children Hospital Oct 08 2011
28. CD56 positivity is a poor prognostic factor in AML patients undergoing stem cell transplant. EBMT 2011. (Poster presentation)
29. Long-term survival of 2Gy TBI and Fludarabine as the RIC conditioning in the treatment of repeated relapsed lymphoma. EBMT 2011. (Poster presentation)
30. Long-term survival of mantle cell lymphoma -A single institution experience in Taiwan. European Hematology Association 2010 Annual Meeting, Barcelona, Spain.
31. Micafungin prophylaxis in hematopoietic stem cell transplantation – A single institution experience. European Hematology Association 2010 Annual Meeting, Barcelona, Spain.
32. Allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute leukemia – a single-center experience. EBMT 2010. (Poster presentation)
33. Velcade Combination Chemotherapy and reduced intensity allogeneic stem cell transplantation for the Treatment of Relapsed Mantle Cell Lymphoma. (Oral presentation) 2010 Annual Meeting of Chinese Hematology Society.
34. Salvage Treatment for Relapsed Mantle Cell Lymphoma. Asia-Pacific Bone Marrow Transplantation 2010 Annual Meeting, Phuket, Thailand.
35. Hematopoietic Stem Cell Transplant versus Chemotherapy for multiple myeloma. Asia-Pacific Bone Marrow Transplantation 2010 Annual Meeting, Phuket, Thailand.
36. Stem Cell Transplantation for Multiple Myeloma. Seasonal Meeting of Taiwan Hematology Association. Tainan, Aug 14, 2014.
37. Frontline and Salvage Treatment of Multiple Myeloma. Seasonal Meeting of Southern Taiwan Hematology Association, Ping-Tong, Aug 28, 2010.
38. Overview of Iron Threat for BMT patients. Seasonal Meeting of Northern Taiwan BMT Association, Taipei, Sep 10, 2010.
39. Clinical cases of Nilotinib treatment for Imatinib failure CML patients. CML Summit. Taipei. May 30, 2010.
40. Current Status and Clinical Challenges for Treatment of CML in Taiwan. CML Summit. Taipei. Nov 20, 2010.
41. ASH Update in CML New TKI Therapy. Taiwan Hematology Meeting Jan 31 2010.
42. Tasigna Clinical Data Update Taiwan Hematology Meeting Jan 30 2010.
43. Long-term Survival of Mantle Cell Lymphoma – A Single Institution Experience. Oral presentation at VGH-Taipei Meeting. Mar 10 2010.
44. Addition of Anti-Thymocyte Globulin Could Reduce the GVHD and not Increase Mortality in Unrelated Stem Cell Transplantation. Goteborg, EBMT 2009. (Poster presentation)
45. Treatment Algorithm of Relapsed Leukemia after Hematopoietic Stem Cell Transplantation. 2009 Annual Meeting of Asia-Pacific Blood and Marrow Transplantation, Seoul, South Korea (Poster presentation).
46. Micafungin Prophylaxis in Hematopoietic Stem Cell Transplant. 2009 Annual Meeting of Asia-Pacific Blood and Marrow Transplantation, Seoul, South Korea (Poster presentation).
47. Treatment of Relapsed Acute Leukemia after Hematopoietic Stem Cell Transplantation. (Oral presentation) 2009 Annual Meeting of Chinese Hematology Society.
48. The Shift of Treatment for Nasal and Nasal-type NK/T cell lymphoma, ten years’ experience and prognostication analysis in a single institution. 2007 Annual Meeting of European Hematology Association. (Poster presentation)
49. Cytomegalovirus Infection of Post-Hematopoietic Stem Cell Transplant in Seropositive Population. 2008 Annual Meeting of Asia-Pacific Blood and Marrow Transplantation, Taipei.
50. TBI 2Gy and Fludarabine as the Nonmyeloablative conditioning in relapsed lymphoma – A single institute experience. Hong-Kang, Annual Meeting of HKSH 2009 and CBMT Forum (Poster presentation).
51. Non-myeloablative allogeneic peripheral blood stem cell transplantation for relapsed lymphoma -A single institute experience. 2008 Seasonal Meeting of Chinese Hematology Society.
52. Comparative Outcomes between Related and Unrelated Allogeneic Hematopoietic Stem Cell Transplantation -the experience from a single institute. 2008 Annual Meeting of Chinese Hematology Society.
53. The Shift of Treatment for Nasal and Nasal-type NK/T cell lymphoma. 2007 Annual Meeting of Chinese Hematology Society.
54. Treatment of Mantle cell lymphoma. 2006 Annual Meeting of Chinese Internal Medicine Society Satellite Meeting.
55. Failure Pattern of Stem Cell Transplant. 2006 Annual Meeting of Chinese Hematology Society.
56. The temporal change of hemoglobin, Anti-A and Anti-B titers, and the necessity of packed cell transfusions before and after the treatment of Rituximab. 2005 Annual Meeting of Chinese Hematology Society.
57. Pulmonary complication in stem cell transplantation. 2005 Annual Meeting of Chinese Hematology Society.
58. Medical Treatment of Metastatic Cancer to the Bone. 2005 Annual Meeting of Chinese Orthopedic Society.
59. Treatment of Peripheral T cell Lymphoma. 2004 Annual Meeting of Chinese Hematology Society.
60. Case report-Prostate lymphoma with intravascular lymphomatosis. 2003 Annual Meeting of Chinese Hematology Society.